1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Pomalidomide
Trade Name:
Pomalyst
Manufacturer/Distributor:
Celgene Canada
www.celgenecanada.net
Classification:
Antineoplastic agent; immunmodulator
ATC Class:
L04AX - Other immunosuppressants
Status:
active
Notice of Compliance (yyyy/mm/dd):
2014/01/20
Date Marketed in Canada (yyyy/mm/dd):
2014/02/24
Presentation:
Capsule: 1 mg. DIN: 02419580
Capsule: 2 mg. DIN: 02419599
Capsule: 3 mg. DIN: 02419602
Capsule: 4 mg. DIN: 02419610
Comments:
Pomalidomide is indicated for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen.
POMALYST™ is only available through a controlled distribution program called RevAid®. Under this program, only prescribers and pharmacists registered with the program are able to prescribe and dispense the product. In addition, POMALYST™ can only be dispensed to patients who are registered and meet all the conditions of the RevAid® program.
Back to:
Drug Product Listings 
